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Adenosine is a widespread neuromodulator within the CNS and its extracellular level is
increased during hypoxia or intense synaptic activity, modulating pre- and postsynaptic
sites. We studied the neuromodulatory action of adenosine on glutamatergic currents
in the hippocampus, showing that activation of multiple adenosine receptors (ARs) by
basal adenosine impacts postsynaptic site. Specifically, the stimulation of both A1R and
A3R reduces AMPA currents, while A2AR has an opposite potentiating effect. The effect
of ARs stimulation on glutamatergic currents in hippocampal cultures was investigated
using pharmacological and genetic approaches. A3R inhibition by MRS1523 increased
GluR1-Ser845 phosphorylation and potentiated AMPA current amplitude, increasing
the apparent affinity for the agonist. A similar effect was observed blocking A1R with
DPCPX or by genetic deletion of either A3R or A1R. Conversely, impairment of A2AR
reduced AMPA currents, and decreased agonist sensitivity. Consistently, in hippocampal
slices, ARs activation by AR agonist NECA modulated glutamatergic current amplitude
evoked by AMPA application or afferent fiber stimulation. Opposite effects of AR
subtypes stimulation are likely associated to changes in GluR1 phosphorylation and
represent a novel mechanism of physiological modulation of glutamatergic transmission
by adenosine, likely acting in normal conditions in the brain, depending on the level of
extracellular adenosine and the distribution of AR subtypes.
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INTRODUCTION
Purinergic signaling is emerging as one important mechanism of integrating functional activity
between neurons, glial and vascular cells in the brain, through the action of both ATP
and adenosine signaling (Burnstock et al., 2011). Adenosine is a cellular metabolite formed
by the breakdown of adenine nucleotides and is physiologically present at nanomolar to
micromolar concentrations inside and outside the cells (Fredholm, 2007). It represents an
endogenous modulator of brain functions, fine-tuning glial function (Boison, 2007), blood flow
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(Kusano et al., 2010), but also inhibitory and excitatory
synaptic transmission (Ribeiro and Sebastião, 2010); moreover,
in the nervous system, the level of extracellular adenosine rises
following brain damage, which occurs after stroke, ischemia, and
epileptic seizures (Ribeiro et al., 2003).
Basal extracellular adenosine concentration depends on the
activity of both membrane nucleoside transporters (Parkinson
et al., 2011; Diógenes et al., 2014), and extracellular ecto-
nucleotidases (Zimmermann et al., 2012). It has been reported
that the synaptic concentration of adenosine, tightly controlled
by astrocytes and neurons, is usually higher than the intracellular
one, and tonically modulates synaptic activity acting on
adenosine receptors (ARs) A1R and A2AR to regulate pre or
post synaptic functions (Sebastião and Ribeiro, 2014). The best
characterized effect of adenosine is the presynaptic modulation
of glutamatergic transmission (Dunwiddie and Fredholm,
1984): presynaptic activation of A1R reduces glutamate release
(Sebastião et al., 1990), while activation of A2AR increases
glutamatergic transmission (Sebastião and Ribeiro, 1992; Cunha
et al., 1994; Lopes et al., 2002).
It is also known that adenosine may modulate synaptic
transmission also acting at the postsynaptic level (Haas and
Greene, 1984; Sebastião and Ribeiro, 2014), regulating the activity
of neurotransmitter receptors. Specifically, A1R activation
inhibits AMPA andNMDA induced currents in the hippocampus
(de Mendonça et al., 1995; Piccinin et al., 2010; Dias et al.,
2012), while A2AR stimulation increases the amplitude of AMPA-
evoked and miniature postsynaptic currents enhancing GluR1
phosphorylation at Ser845 (Dias et al., 2012). By contrast, few
studies have focused on the role of A3 receptors (A3R) in synaptic
modulation, although these receptors have been identified in
neurons (Lopes et al., 2003; Rebola et al., 2005), astrocytes and
microglial cells (Boison et al., 2010) and have a potential impact
in glutamatergic modulation and synaptic plasticity (Costenla
et al., 2001; Maggi et al., 2009; Piccinin et al., 2010), in addition
to their involvement in pain modulation (Ford et al., 2015) and
neuroprotection (Chen et al., 2006; Pugliese et al., 2007; Dennis
et al., 2011; Rosito et al., 2012, 2014).
In this study we demonstrate the ability of A3R to
negatively modulate postsynaptic AMPA receptors through the
reduction of GluR1 phosphorylation level.Moreover, this effect is
synergistic with the A1R mediated reduction of AMPA currents,
and counteracts the potentiating effect of A2AR activation.
Importantly, we show that adenosine modulation is tonically
active. Hence, the concomitant activity of A1R, A2AR, and A3R
tightly tunes glutamatergic synapses, setting the properties of
AMPA receptors functioning in basal conditions.
MATERIALS AND METHODS
Animals
Procedures using laboratory animals were in accordance with
the Italian and European guidelines and were approved by the
Italian Ministry of Health in accordance with the guidelines
on the ethical use of animals from the European Community
Council Directive of 22 September 2010 (2010/63/EU). All efforts
were made to minimize the number of animals used and their
suffering.
Primary Hippocampal Neuronal Cultures
Hippocampal neuronal cultures were prepared as reported in Di
Angelantonio et al. (2014), from newborn (P0-P1) C57BL/6 and
KO mice of either sex (Charles River Laboratory). In brief, after
careful dissection from diencephalic structures, the meninges
were removed and the hippocampi were chopped and digested in
1.25 mg/ml trypsin for 20 min at 37◦C. Cells were mechanically
dissociated and plated at a density of 105 in poly-L-lysine coated
glass coverslip (12 mm diameter) in serum-free Neurobasal
medium, supplemented with B27 plus 2 mM L-glutamine and
100 μg/ml gentamicin (neuronal culture medium). Then, cells
were kept at 37◦C in 5% CO2 for 10–13 days with medium
replacement (1:1 ratio) three times per week. With this method
we obtained cultures composed by 60–70% neurons, 30–35%
astrocytes, and 4–5% microglia, as determined with β-tubulin III,
glial fibrillary acidic protein (GFAP), and isolectin IB4 staining
(Lauro et al., 2008). The same procedure was followed to prepare
rat hippocampal culture used for some immunoblot experiments.
Glial Primary Cultures
Primary cortical glial cells were prepared from P0–P2 mice.
Cerebral cortices were chopped and digested in 30 U/ml papain
for 40 min at 37◦C and gently triturated. The dissociated cells
were washed, suspended in Dulbecco’s Modified Eagle Medium
(DMEM, GIBCO) with Glutamax with 10% FBS (Invitrogen) and
plated at a density of 9–10 × 105 in 175 cm2 cell culture flasks.
At confluence (10–14 days in vitro, DIV), glial cells were shaken
for 2 h at 37◦C, to detach and remove microglial cells. These
procedures gave almost pure astrocytes cell population (4–6% of
microglia contamination), as verified by staining with GFAP and
isolectin IB4 (Rosito et al., 2012).
Slice Preparation
Hippocampal slices were routinely prepared from 14- to 20-
days old C57BL/6 mice (WT), A1R knockout mice (A1R KO;
Johansson et al., 2001), and the A3R knockout mice (A3R KO;
Salvatore et al., 2000). The latter two groups of mice were
backcrossed at least 10 times on a C57BL/6 background. Mice
were decapitated under halothane anesthesia, and whole brains
were rapidly removed and incubated in chilled artificial CSF
(ACSF) for 15 min. Transverse hippocampal slices (250 μm)
were cut at 4◦C, using a Vibratome (DSK, Dosaka EM, Kyoto,
Japan). Before use, slices were maintained for at least 1 h at
room temperature (22–25◦C) in oxygenated (95% O2, 5% CO2)
ACSF, containing the following (in mM): 125 NaCl, 2.5 KCl, 1.25
NaH2PO4, 26 NaHCO3, 2 CaCl2, 1 MgCl2, and 10 glucose, pH
7.35. All recordings were performed at room temperature on
slices submerged in ACSF in the recording chamber. The ACSF
was perfused at a rate of 1 ml/min.
Patch-clamp Recordings
Patch-clamp recordings were obtained using glass electrodes (3–
5 M) filled with the following intracellular solution (in mM):
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140 KCl, 2 MgCl2, 10 HEPES, 2 MgATP, 0.5 EGTA; pH 7.3, with
KOH. During experiments, cultured neurons were continuously
superfused with normal extracellular solution (NES) containing
(in mM): 140 NaCl, 2.5 KCl, 2 CaCl2, 2 MgCl2, 10 HEPES-NaOH,
and 10 glucose (pH 7.3), added with tetrodotoxin (0.2μM), using
a gravity driven perfusion system, consisting of independent
tubes for standard and agonist-containing solutions, connected
to a fast exchanger system used to delivery all agonists (RSC-
100; Bio-Logic). To activate glutamate receptors in hippocampal
neurons in acute slices, AMPA was delivered together with
cyclothiazide (25 μM; Tocris Cookson) by pressure application
(5–15 psi, 10–100 ms; Picospritzer II, General Valve, Fairfield, NJ,
USA) from glassmicropipettes positioned above the slice over the
soma of the recorded neuron. All other agonists were applied to
hippocampal slices by bath perfusion.
In all recordings, AMPA was delivered together with
cyclothiazide, to avoid fast receptor desensitization (Fucile
et al., 2006) that could mask adenosine mediated AMPA
receptor modulation. Cyclothiazide was always delivered in
co-application with the agonist. Agonist concentration–current
curves were constructed applying to each cell two or more
different concentrations of agonist (10 nM–100 μM) at 60–120 s
intervals and normalizing the current response to the plateau
value, tested in all cells. Averaged data were best-fitted using
Origin 7 (OriginLabCorp., Northampton, MA, USA) to the Hill
equation:
Inorm = 1/(1 + (EC50)nH/[Agonist]nH)
Where Inorm is the normalized current response, EC50 is the
agonist concentration yielding half-maximal current response
and nH is the Hill coefficient.
Membrane currents, recorded with a patch-clamp amplifier
(Axopatch 200B; Molecular Devices, Foster city, CA, USA), were
filtered at 2 kHz, digitized (10 kHz), and acquired with Clampex
10 software (Molecular Devices). The stability of the patch was
checked by repetitively monitoring the input and series resistance
during the experiment, and recordings were discarded when any
of these parameters changed by >10%.
All recordings were performed at 24–25◦C, and cells were
patch clamped at −70 mV.
Cell Stimulation and Western Blot
Analysis
Ten DIV hippocampal cultures were incubated in Locke’s buffer
(in mM): 154 NaCl, 5.6 KCl, 3.6 NaHCO3, 2.3 CaCl2, 1MgCl2, 5.6
glucose, buffered with 5 HEPES (pH 7.4) for 2 h and stimulated
for 30 min with MRS1523 (100 nM).
Cells were then washed with PBS, scraped and lysed (Tris-
HCl 50 mm pH 7.5, NaCl 150 mm, EGTA 1 mm, EDTA
1 mm, 1%, Triton X-100, 0.1% SDS, phosphatase and protease
inhibitor mixture). Protein concentration was determined by
BCA assay (Pierce), and the same amounts of proteins (30 μg)
were separated on 10% SDS-PAGE and analyzed by Western
immunoblot using with antibodies specific for phospho-GluR1
Ser845 (Upstate Biotechnology, Lake Placid, NY, USA), and actin
(Sigma). Immunoreactivity was detected by chemiluminescence
(Immun-Star WesternC Kit; Bio-Rad). Specific bands on
chemiluminescence films were quantified by densitometry with
Sigma Gel Software (Jandel Scientific, Erkrath, Germany).
Drugs
SCH5821 (stock solution 10 mM in DMSO), DPCPX (stock
solution 5 mM in DMSO), 2-Cl-IBMECA (stock solution 10 mM
in DMSO), Bicuculline methochloride (stock solution 100 mM),
AMPA (stock solution 100 mM), cyclothiazide (stock solution
50 mM in DMSO) and Tetrodotoxin citrate (stock solution
1 mM) were purchased from Tocris Bioscience, Bristol, UK.
MRS1523 (stock solution 100 mM in DMSO) and all other drugs
used were purchased from Sigma–Aldrich, Milan, Italy. Where
not indicated, all drugs were dissolved in water.
Drug Application
During electrophysiological measurements, neurons were
continuously superfused with NES, using a gravity driven
perfusion system, consisting of independent tubes for standard
and agonist-containing solutions, connected to a fast exchanger
system (RSC-100; Bio-Logic) positioned 50–100 μm from the
cell. Antagonists were usually acutely applied through parallel
tubes of the same perfusion system or were pre-incubated for 1 h
(37◦C) and then continuously applied during the experiments.
Data Analysis
Data, analyzed offline, are presented as mean± SEM; we used the
QuantityOne (Biorad) program for the densitometric analysis of
all immunoblots. Origin 7 (Origin software; Microcal Software,
Northampton, MA) and Sigmaplot 11 (Jandel scientific) software
were used for statistical analysis. Paired and unpaired t-test and
one-way ANOVA were used for parametrical data, as indicated;
Holm–Sidak test was used as post hoc test; Mann and Withney
test for non-parametrical data.
RESULTS
Modulation of AMPA Receptors by Basal
Adenosine
It is well known that adenosine is present in brain extracellular
space, as well as in neural preparations, such as brain slices
or neuronal cultures. When we removed basal adenosine in
hippocampal cultures with adenosine deaminase (ADA; 1 U/ml;
10 min), we observed a slow increase in the amplitude of currents
evoked by AMPA application (10 μM; plus cyclothiazide, CTZ,
25 μM; to 120 ± 4%, n = 5, p < 0.05; Figure 1A). This
result suggests that adenosine present in the extracellularmedium
tonically depresses glutamatergic transmission bymodulating the
amplitude of AMPA currents.
To unveil the involvement of AR subtypes in AMPA current
modulation, cultures were treated with specific ARs antagonists,
in order to establish the possible contribution of A1R, A2AR, and
A3R.
When control cultures were superfused with the A3R specific
antagonist MRS1523 (100 nM, 8 min), we observed a significant
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FIGURE 1 | Tonic activation of adenosine receptors modulates AMPA currents in mouse hippocampal neurons. (A) time course and sample traces of
AMPA current (AMPA 10 μM, CTZ 25 μM) potentiation induced by acute treatment with Adenosine deaminase (ADA, 1 U/ml, n = 5; p < 0.05) in cultured
hippocampal neurons. (B) Left, time course of AMPA current modulation by acute treatment with adenosine receptors antagonists blocking specifically: A3R
(MRS1523, 100 nM, n = 5, purple), A3R + A1R (MRS1523 + DPCPX, n = 5, green) or A2AR (SCH58261 30 nM, n = 5, orange). Application of all drugs starts at
t = 0, gray bar. Right, sample traces of AMPA currents in control (black) and in the presence of MRS1523 (purple) or SCH58261 (orange).
increase in the amplitude of AMPA currents (to 123.1 ± 7.9%,
n= 5; p< 0.05; Figure 1B). A similar effect was obtained treating
cultures with the A1R specific antagonist DPCPX (100 nM),
causing current amplitude increase to 123.8 ± 13.5% (n = 10,
p< 0.05; not shown). Interestingly, when both A3R andA1R were
blocked the current increase was significantly higher, suggesting
an additive effect of the two antagonist (n = 5, p < 0.05 vs.
MRS1523 or DPCPX alone, one way ANOVA, Holm–Sidak,
Figure 1B).
Conversely, the application of the specific A2AR antagonist
SCH58261 (30 nM; 8min) caused a decrease in current amplitude
(to 80.8 ± 4.6%; n = 5, p < 0.05; Figure 1B).
In addition, prolonged treatment of hippocampal cultures
with specific ARs antagonists (30 min preincubation and during
recordings) significantly affected the AMPA current response
amplitude (10 μM plus CTZ, 25 μM; Table 1); the mean
current amplitude was in fact significantly enhanced byMRS1523
or DPCPX treatment, while it was reduced by SCH58261
(Table 1).
These data indicate that in hippocampal cultures, ARs
are tonically active due to the presence of adenosine in the
extracellular medium, and that this has a modulatory effect on
glutamatergic currents. The stimulation of A3R or A1R subtypes
TABLE 1 | Dose response parameters of AMPA response.
Peak amplitude (pA) (n) EC50 (µM) (n) nH
WT 678 ± 64 (53) 5.4 ± 0.7 (32) 1.6 ± 0.1
MRS1523 1740 ± 520 (13)∗∗ 1.3 ± 0.3 (11)∗∗ 1.9 ± 0.3
DPCPX 1420 ± 180 (12)∗∗ 1.6 ± 0.2 (12)∗ 2.1 ± 0.4
SCH58261 504 ± 54 (9)∗ 8.6 ± 0.5 (9)∗∗ 1.4 ± 0.3
A3R KO 1020 ± 93 (33)∗∗ 1.2 ± 0.3 (11)∗∗ 1.8 ± 0.2
A1R KO 888 ± 130 (20)∗ 1.9 ± 0.3 (8)∗ 1.7 ± 0.3
A2AR KO 754 ± 210 (13) 10.5 ± 0.6 (12)∗∗ 1.5 ± 0.1
Data represent means ± SEM (number of cells) of: Column 2, mean Peak amplitude
response to a test dose of agonist (AMPA 10 μM); Column 3, 4 fit parameters for
dose-response curve fitted by Hill equation. ∗p < 0.05 and ∗∗p < 0.01, significantly
different from control value in WT untreated neurons, as specified in Column 1.
causes a tonic depression of AMPA receptors, while A2AR
activation potentiates them; under basal condition, the inhibitory
tone prevails, suggesting a predominance of A1R, A3R-mediated
AMPARmodulation.
AMPA Receptors Affinity is Modulated by
the Selective Activation of ARs
To understand how ARs activation could affect the AMPA
receptor function, we measured the AMPA concentration–
current response curve in hippocampal neurons, both in control
conditions or interfering with basal ARs activation. In particular,
to unveil the contribution of single AR subtypes to GluRs
modulation, we selectively abolished specific ARs activity either
pharmacologically or genetically, using hippocampal cultures
derived from A1R, A2AR od A3R KO mice.
WhenWT cells were treated withMRS1523 (100 nM), to block
A3R, we observed a leftward shift in the AMPA concentration–
response curve (Figure 2A), corresponding to an increase in the
agonist apparent affinity (Figure 2A;Table 1, n= 11) with a EC50
value significantly different from the one observed in control
conditions (Table 1, n = 32, p < 0.01), suggesting that basal A3R
activation reduces GluR sensitivity for the agonist. Consistently,
we observed an increase in the agonist affinity in hippocampal
cultures derived from A3R KO mice (n = 11; Figure 2A; Table 1,
p < 0.01).
Analogously, both the pharmacological inhibition by DPCPX
(10 nM; n = 12) and the genetic deletion of A1R (hippocampal
cultures derived from A1R KO mice), caused an increase in
AMPA potency (Table 1, n = 8; p < 0.05).
Conversely, when A2ARwas inhibited by SCH58261 or deleted
in A2AR KO cultures, the apparent affinity for AMPA was
decreased (n = 9, p < 0.05 and n = 12, p < 0.01 respectively;
Figure 2B; Table 1).
Altogether, these data indicate that GluRs functional
properties are finely tuned by activation of different AR subtypes
by basal adenosine. The sensitivity of GluRs is modulated in
opposite directions by activation of ARs and in particular, A3R
or A1R decrease agonist affinity, while it is increased by A2AR.
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FIGURE 2 | Basal activation of AR subtypes changes the apparent
affinity for AMPA. (A) AMPA dose response curves (+ CTZ 25 μM) obtained
in cultured hippocampal neurons in control (black, n = 32), in the presence of
A3R antagonist MRS1523 (100 nM, n = 11, purple) and in neurons from A3R
KO mice (n = 11, magenta). Inserts: sample traces representing current
responses to 1, 10, and 100 μM AMPA (+ CTZ 25 μM) in WT and A3R KO
hippocampal neurons. (B) AMPA dose response curves (+ CTZ 25 μM)
obtained in cultured hippocampal neurons in the presence of A2AR antagonist
SCH58261 (30 nM, n = 9, orange) and in neurons from A2AR KO mice
(n = 12; red; control condition in black). Inserts: representative current
responses to 1, 10, and 100 μM AMPA (+ CTZ 25 μM) in A2AR KO
hippocampal neurons.
Neuronal A3R Regulates AMPA
Receptors Function Through Modulation
of GluR1-Ser845 Phosphorylation
To investigate the cellular and molecular determinants
underlying the A3R mediated modulation of AMPA currents,
we performed experiments using the specific A3R agonist
2-Cl-IBMECA. To remove basal activation of ARs, control
hippocampal cultures were treated with ADA (1 U/ml, 1 h pre-
application and during the experiment) and current amplitude
was monitored during the application of the specific A3R agonist
2-Cl-IBMECA. Consistently with the above reported results
with A3R antagonist, the application of 2-Cl-IBMECA (10 nM,
10 min) reduced the AMPA current amplitude (to 60 ± 11%,
n = 12, p < 0.01; Figure 3A).
As expected, in cultures prepared from A3R KO mice,
2-Cl-IBMECA failed to reduce AMPA current (103 ± 3%;
n = 13; p = 0.67; Figure 3A), confirming that the observed
effect was ascribable to specific A3R stimulation. To evaluate
the possible contribution of glial A3R in the AMPA current
modulation, we explored if glial A3R stimulation could
rescue AMPA current modulation. To this purpose, A3R
KO hippocampal cultures were seeded on a feeding layer
of either A3R KO or WT glial cells: 2-Cl-IBMECA was
ineffective both in A3R KO cultures seeded on WT glia
(n = 14, p = 0.84; Figures 3A,B) and co-cultured with A3R
KO glia (n = 12, p = 0.91), strongly indicating that 2-Cl-
IBMECA acts specifically on neuronal A3R to modulate AMPA
function.
Since A3R stimulation reduces cAMP accumulation (Zhou
et al., 1992), and PKA is responsible for GluR1 phosphorylation
at Ser845 (Banke et al., 2000), we studied the contribution of
A3R in AMPAR phosphorylation to understand the intracellular
pathway leading to the AMPA current modulation. To address
this issue, ATP was substituted in the intracellular solution
by ATPγS, in order to promote irreversible substrate thio-
phosphorylation (Eckstein, 1985) and thus to prevent the
AMPAR dephosphorylation. As reported in Figure 4A, in this
experimental condition 2-Cl-IBMECA (10 nM, ADA 1U/ml,
n = 6, p < 0.05) failed to reduce the AMPA current amplitude.
Consistently, MRS1523 (100 nM) application failed to potentiate
AMPA-mediated currents when neuronal PKA was inhibited
by intracellular perfusion with KT5720 (Figure 4B; n = 6;
p = 0.83).
To test whether A3R modulation of AMPA currents could
be associated to changes in GluR1 phosphorylation level, we
exposed hippocampal cultures to MRS1523 (100 nM, 30 min)
and evaluated the level of GluR1 phosphorylation at Ser845.
Quantitative western blot analysis showed that, in MRS1523
treated cultures, the Ser845 phosphorylation increased to
125.6± 11.8% (n= 13, p< 0.03; Figure 4C), indicating that tonic
A3R activity reduces GluR1 phosphorylation. Altogether, these
results indicate that the A3R activationmodulates GluR functions
through receptor dephosphorylation.
Modulation of Postsynaptic AMPA
Receptors in Acute Hippocampal Slices
by A1R, A2AR and A3R Activation
To disclose the postsynaptic modulation of glutamatergic
currents by ARs activation in hippocampal slices, we recorded the
effect of the high affinity AR agonist N-ethyl 1-5′ carboxamido
adenosine (NECA) application on currents evoked by repetitive
pressure application of AMPA (100 μM, plus CTZ 25μM) on
CA1 pyramidal neurons. Prolonged NECA application (100 nM;
25 min) caused a reduction in the AMPA current amplitude (to
86.9 ± 2.2%, p < 0.01 paired t-test; n = 6; Figure 5A), which
did not recover within 20 min after drug washout (Figure 5A).
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FIGURE 3 | AMPARs function modulation requires neuronal A3R activation. (A) Reduction of AMPA current amplitude induced by the application of A3R
agonist 2-Cl-IBMECA in cultured hippocampal neurons treated with Adenosine deaminase (1 U/ml, 1 h preincubation + perfusion); bar chart representing the effect
observed in WT cultures (black; n = 12); or A3R KO cultures (magenta; n = 13); gray column represents the effect of 2-Cl-IBMECA in A3R KO cultures in the
presence of WT glial cells (n = 12). (B) Sample traces showing the effect of 2-Cl-IBMECA on AMPA currents in hippocampal neurons from WT (top) and A3R KO
(bottom) mice, co-cultured with WT glial cells. ∗∗p < 0.01.
We used combinations of specific ARs antagonist to disclose
the contribution of single receptor subtypes (Figure 5B). In the
presence of DPCPX (100 nM) plus SCH58261 (30 nM), allowing
only the activation of A3R, NECA caused a reduction of the
AMPA current amplitude (to 78.6 ± 4.5%; n = 5; p < 0.01,
paired t-test), followed by a slow recovery after drug withdrawal.
Smaller depression (to 90.0 ± 3.6%; n = 6, p < 0.05, paired
t-test) was observed when NECA was applied in the presence of
SCH58261 plus MRS1523 (100 nM), allowing only the activation
of A1R (p < 0.05 respect to NECA in the presence of DPCPX
plus SCH58261; One way ANOVA, Holm–Sidak, Figure 5C).
Conversely, in the presence of DPCPX plus MRS1523, NECA
caused AMPA current potentiation, due to A2AR stimulation (to
108.5 ± 5.1%, n = 6, p < 0.05, paired t-test). All together, these
results indicate that also in hippocampal slices, activation of A1R,
A2AR and A3R modulates AMPA receptors.
To verify whether ARs modulation of AMPA receptors
might affect glutamatergic synaptic transmission, we recorded,
in CA1 pyramidal neurons, the excitatory postsynaptic currents
(EPSCs) evoked by Schaffer collaterals stimulation. In this
condition, we observed that basal adenosine, present in the
slice preparation, modulates glutamatergic synaptic currents
being EPSC amplitude increased by acute ADA application
(Supplementary Figure S1A). Moreover, as revealed using
A1RKO and A3RKO mice, the application of high dose of
adenosine induced an EPSC depression depending on both A1R
and A3R (Supplementary Figures S1B,C). In addition, NECA
application caused a reduction of EPSCs amplitude (n = 7;
p< 0.05; Figure 6A), without affecting the paired pulse ratio (not
shown), supporting a postsynaptic action of NECA that largely
depends on the A3R activation. Indeed, NECA-mediated EPSCs
depression was significantly smaller when A3R was blocked
(MRS1523 100 nM, n = 4, p < 0.05 respect to NECA alone,
one way ANOVA, Holm–Sidak; Figure 6B), and it was abolished
when A1R and A2AR blockers (DPCPX 100 nM, SCH58261
30 nM) were simultaneously added (n = 7, p < 0.01 respect to
NECA alone, one way ANOVA, Holm–Sidak; Figure 6B).
These data confirm that the A3R activation may modulate
glutamatergic synaptic transmission by a postsynaptic
mechanism affecting AMPA receptor functions.
DISCUSSION
We report here that adenosine present in the extracellular milieu
may tonically regulate the function of AMPA receptors acting
on A1R, A2AR, and A3R. Our data show that adenosine exerts
multiple effects on glutamatergic transmission, modulating in
opposite direction the apparent affinity of AMPA receptors,
depending on AR subtypes. Our study is particularly focused on
the effects of A3R stimulation, highlighting the role of this AR
subtype in the modulation of glutamatergic transmission.
We propose that the A3R modulation of AMPA receptors
is based on the alteration of the phosphorylation balance, at
GluR1-Ser845, leading to changes in the apparent agonist affinity
of the receptor. It is well known that phosphorylation affects
the properties of the glutamate receptors (Banke et al., 2000)
shifting the sensitivity to the transmitter/agonist (Lax et al.,
2002); similar mechanisms could be involved in adenosine-
based forms of synaptic modulation and plasticity (Ragozzino
et al., 2006; Lauro et al., 2008; Piccinin et al., 2010; Scianni
et al., 2013). Our data show that the A3R stimulation causes a
depression of the AMPA currents, which is likely associated with
receptor dephosphorylation, since it is absent in the presence
of ATPγS which promotes irreversible thio-phosphorylation of
substrates (Eckstein, 1985). Consistently, the treatment with the
specific A3R blocker MRS1523 (i) causes the increase in the
AMPA current amplitude, as confirmed in experiments on A3R
KO cultures; (ii) is associated to the increase in the level of
GluR1-Ser845 phosphorylation and (iii) is blocked by the PKA
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FIGURE 4 | A3R dependent AMPARs modulation requires GluR1
dephosphorylation. (A) Time course of the effect of the A3R agonist
2-Cl-IBMECA on AMPA current amplitude in the continuous presence of ADA
(1 U/ml, 1 h preincubation) in control condition (black, n = 12) and after
substitution of intracellular ATP with the thiophosphorylating agent ATPγS
(n = 6). (B) Bar chart and sample traces displaying mean AMPA current
potentiation induced by A3R antagonist MRS1523 in control and in the
presence of PKA blocker KT5720 (n = 6). (C) Representative immunoblot and
quantitative western blot analysis of the effect of MRS1523 on the level of
basal Glur1 Ser845 phosphorylation (n = 13). ∗p < 0.05, ∗∗p < 0.01.
antagonist KT5720. Indeed, adenosine is known to act through
intracellular pathways involving PKA (Fredholm et al., 2001a),
potentially interfering with the phosphorylation of GluRs. In
line with this, it has been shown that A2ARs stimulation leads
to the potentiation of glutamatergic currents in hippocampal
neurons and to GluR1 phosphorylation (Dias et al., 2012). It has
to be considered that both A1R and A3R are coupled to Gi/Go
proteins, and that their activation leads to a decrease in the level
of cAMP (Palmer et al., 1995; Lorenzen et al., 1998). It can be
thus hypothesized that the concomitant block of A1R and A3R
will consistently increase the level of cAMP, possibly leading to
a bigger effect respect to the one observed with a single receptor
antagonist.
The effect of ARs stimulation on the amplitude of AMPA-
evoked currents is observed both in hippocampal cultures and
in acute slices. It can be speculated that the modulation of
agonist affinity may have relevance only on extrasynaptic GluRs,
physiologically activated by low concentration of glutamate, as it
is has been shown for adenosine modulation of GABA receptors
(Rombo et al., 2014). Indeed, our results show that the ARs
stimulation by NECA, in particular A3R activation, also affects
glutamatergic synaptic transmission in hippocampal slices, where
GluRs are activated by high transmitter concentration (Clements,
1996), depressing EPSCs amplitude. Moreover, EPSCs depression
is not associated to a change in the paired pulse ratio, indicating
a postsynaptic mechanism (Dobrunz and Stevens, 1997).
It should be noted that EPSCs depression induced by NECA
shows a peculiar pharmacology, likely reflecting a preferential
action of the agonist on postsynaptic A3R, due to the higher
NECA affinity for A3R compared to other ARs (Müller, 2003;
Müller and Jacobson, 2011; Dal Ben et al., 2014). Indeed,
in our experimental conditions, extracellular adenosine might
activate or desensitize presynaptic A1R. Thus, in addition to
the well known A1R presynaptic modulation (Sebastião et al.,
1990; Sebastião and Ribeiro, 2000, 2009; Boison, 2007), the
ARs stimulation may depress EPSCs by an A3R-dependent
postsynaptic mechanism. The involvement of A3R in the
glutamatergic synaptic modulation has been previously reported
(Brand et al., 2001; Costenla et al., 2001; Piccinin et al.,
2010), particularly in hypoxic conditions (Hentschel et al., 2003;
Pugliese et al., 2007), when the adenosine extracellular level is
highly increased (Fredholm, 2007).
While interpreting the pharmacological results, it should be
considered that basal adenosine may affect ARs to different
extent; due to their desensitization properties (Klaasse et al.,
2008) and that phenomena of re-sensitization may occur (Kompa
and Summers, 1999). In this respect, we consider convincing the
consistency of data obtained with pharmacological and knock out
approaches.
Results from this study clearly point to a role of basal
adenosine in glutamatergic modulation; our data from
hippocampal cultures show that removing different ARs,
either by pharmacological or genetic approaches, causes changes
in the functional properties of AMPA receptors (current
amplitude and affinity for the agonist), pointing to tonic receptor
modulation by ambient adenosine. Indeed, the AMPA current
reduction induced by 2-Cl-IB-MECA was more pronounced in
the presence of ADA (see Piccinin et al., 2010), suggesting that
basal adenosine might occlude the effect of exogenous agonist
application.
It could be speculated that ADAmight modulate per seAMPA
receptor activity, however, although it has been hypothesized
the ability of ADA to act independently from its enzymatic
activity (Franco et al., 1997; Yamashita et al., 2012), no data have
been reported concerning the effect of extracellular ADA on the
modulation of neurotransmitter receptors.
It should be noted that purines are released by brain cells
through different mechanisms (Latini and Pedata, 2001) and
that adenosine concentration may rise to the nanomolar range
in hippocampal slices (Dale et al., 2000). It can be speculated
that this situation does not reflect the physiological status,
representing one of the effects connected to slice or culture
unnatural conditions (zur Nedden et al., 2011). On the other
hand, high adenosine level may be present in restricted sites
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FIGURE 5 | N-ethyl 1-5′ carboxamido adenosine (NECA) modulates postsynaptic AMPA receptors through multiple ARs. (A) Time course and
representative traces of AMPA (100 μM plus CTZ 25 μM) current amplitude reduction induced by NECA (t = 25 min) (100 nM) in hippocampal CA1 neurons (n = 6;
p < 0.01). (B,C) Time course and bar chart (at t = 25 min) of the effect of NECA in the presence of combination of ARs antagonists: DPCPX (100 nM) plus
MRS1523 (100 nM) (gray; n = 6; p < 0.01); SCH58261 (30 nM) plus MRS1523 (dark green; n = 6; p < 0.05); DPCPX plus SCH58261 (green; n = 5; p < 0.01).
∗p < 0.05, ∗∗p < 0.01, #p < 0.05, ##p < 0.01.
FIGURE 6 | Modulation of EPSC amplitude by NECA depends on A3R. (A) Left, time course of EPSC depression induced by adenosine receptor agonist NECA
(100 nM) in hippocampal CA1 neurons in from acute slices in control conditions (black; n = 7; p < 0.05 at t = 25 min), in the presence of A3R antagonist MRS1523
(100 nM) (purple; n = 7; p < 0.05 respect to control and NECA alone) and in the presence of DPCPX + SCH58261 + MRS1523 (gray, n = 7). Right, sample EPCSs
recorded in a CA1 pyramidal neuron in control and following NECA application. (B) Bar chart showing the effect of NECA (100 nM) alone (black), in the presence of
the A3R antagonist (MRS1523 100 nM, purple) and in the presence of all three blockers (DPCPX + SCH58261+MRS1523 gray, n = 7). ∗p < 0.05, ∗∗p < 0.01,
#p < 0.05.
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during high level of activity or in pathological conditions (Ribeiro
et al., 2003; Wall and Dale, 2007).
Our results show that adenosine may influence the
glutamatergic neurotransmission through several independent
mechanisms; in particular we show that the modulation of
AMPA receptor by A1R (Lauro et al., 2008) is synergic with
that of A3R, counteracting A2AR-dependent AMPA receptor
potentiation (see also Dias et al., 2012). A1R, A2AR and A3R are
widely expressed at hippocampal synapses, both pre- and post-
synaptically (Lopes et al., 2003; Rebola et al., 2005). ARs are also
expressed on glial cells (Burnstock et al., 2011), however, in our
conditions, the exclusive expression of A3R on glial cells was not
sufficient to rescue the AMPA receptor modulation in A3R KO
cultures, highlighting the role of neuronal A3R in A3R-dependent
modulation.
It should be emphasized that the relevance and even the
sign of adenosine modulation of synaptic transmission and
plasticity (Scianni et al., 2013) will strongly depend on the
level of expression and the regional distribution of different
AR subtypes (Dixon et al., 1996; Fredholm and Svenningsson,
2003; Fukumitsu et al., 2005; Haeusler et al., 2015). We speculate
that this pathway of synaptic modulation could be suitable for
the independent tuning of single synapses (West and Grace,
2002). In addition, it has been proposed that due to time and
space constraints, the source of adenosine may determine the
AR subtype to be activated: adenosine originating from ATP
released by astrocytes seems to target excitatory A2AR (Cunha
et al., 1994), while released adenosine seems to prefer A1R (Lovatt
et al., 2012).
Since A3R is known to have lower affinity for adenosine
(Müller and Jacobson, 2011, but see Fredholm et al., 2001b)
compared to A1R andA2AR, its activity may be relevant especially
after acute brain insults, such as in ischemia and traumatic brain
injury, when the extracellular level of adenosine dramatically
increases (Fredholm, 2007). In particular, the A3R activation can
contribute to reduce over-excitability in order to counteract brain
damage.
CONCLUSION
We show that adenosine, an ubiquitous brain mediator, may tune
synaptic transmission through multiple mechanisms depending
on the AR subtype expression. Suchmechanisms of regulation are
potentially highly relevant in the fine regulation of single synapses
in relation to the level of synaptic activity or other conditions
leading to the local increase of adenosine concentration.
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